Erasca

ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June…

ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class…

23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or…

ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial Erasca previously signed CTCSAs with…

IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in recurrent GBM anticipated in Q1 2022 Early collaboration with GCAR could support…

SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing…

ERAS-801's CNS penetration: four times higher than approved EGFR inhibitorsComprehensive inhibition against oncogenic EGFR vIII and wildtype alterationsImproved outcomes in over 90% of…

Successfully closed $345 million upsized IPO in July 2021 On track to initiate multiple HERKULES Phase 1b/2 trials in 2021 with data readout(s) beginning in 2022 Strengthened…